期刊文献+

血清胱抑素C与β2微球蛋白、尿微量清蛋白检测在2型糖尿病肾病早期诊断中的相关研究 被引量:10

Discussin of Cystatin C and β2-MG, Malbassay in the Diagnosis of Earlyrenal Damage in Type 2 DM
暂未订购
导出
摘要 目的 与血β2微球蛋白(β2-MG)、尿微量清蛋白(mAlb)比较,评价血清胱抑素C(Cysctatin C)测定在2型糖尿病(DM)肾病早期诊断中的研究价值.方法 对120名健康人及246例2型糖尿病患者的Ccr,Cysctatin C,β2-MG,尿mAlb测定结果进行平均值、相关性、敏感度比较分析.2型糖尿病患者按Ccr水平分为DM1组(Ccr≥80 ml/min 1.73 m^2,102例)、Dm^2组(80 ml/min 1.73 m^2〉Ccr≥50ml/min 1.73 m^2,144例).结果 DM1组各指标平均值与对照组相比差异无统计学意义,Dm^2组与对照组相比差异有统计学意义(P<0.01);各组结果具有良好的相关性,Cysctatin C与Ccr相关系数分别为-0.885,-0.550,-0.680,Cysctatin C与β2-MG相关系数分别为0.893,0.721,0.897,Cysctatin C与尿mAlb相关系数分别为0.823,0.676,0.852;各指标中血Cysctatin C测定最为敏感(DM1组47.1%,Dm^2组81.2%).结论 血Cysctatin C测定为2型糖尿病肾病患者早期诊断的理想指标,在常规Scr,Ccr检测的同时联合应用Cysctatin C检测可减低糖尿病肾病的漏诊率. Objective To compare β2-MG and mAlb and assess the clinical value in the detection of Cystatin C in the diagnosis of early renal damage of type 2 DM. Methods Detected the Ccr,Cystatin C,β2-MG and mAlb of 120 healthy persons and 246 cases of type 2 DM and analyzed the average value,correlation and sensitivity of the results. Cases with type 2 DM were divided into DM1 group (Ccr≥80 ml/min 1.73 m^2,102 cases) and DM2 group(80 ml/min 1.73 m^2〉Ccr≥50 ml/min 1.73 m^2,144 cases) according to their Ccr level. Results There was no statistical significance of the average value in DMlcomparing with the contrast group, while there was significant difference in DM2 comparing with the contrast group (P〈0. 01) ;the result of each group had good correlation,the correlation coefficients of Cystatin C and Ccr were - 0. 885,-0. 550 and -0. 680;Cystatin C andβ2-MG were 0. 893,0. 721 and 0. 897;Cystatin C and mAlb were 0. 823,0. 676 and 0. 852 respectively. Among the index,Cys-tatin C detection was most sensitive (46.1% in DM 1,80.6% in DM2). Conclusion Cystatin C detection is ideal in diagnosing early renal damage of type 2 DM. Combining the regular Scr,Ccr detection with Cystatin C detection,the omission diagnoserate of diabetic nephropathy can be decreased.
出处 《现代检验医学杂志》 CAS 2011年第2期107-108,111,共3页 Journal of Modern Laboratory Medicine
关键词 胱抑素C Β2微球蛋白 尿微量清蛋白 早期肾损害 Cystatin C β2-MG mAlb early renal damage
  • 相关文献

参考文献8

二级参考文献22

  • 1阎素英,中华肾脏病杂志,1992年,4期,209页
  • 2周玉红 左力 王梅.MDRD方程预测肾小球滤过率的临床应用评价[J].中华肾脏病杂志,2004,20:30-34.
  • 3Randers E, Erlandsen EJ. Serum Cystatin C as an endogenous marker of the renal function - a review. Clin Chem Lab Med , 1999,37:389-395.
  • 4Mojimintyi OA, Abdella N, George S. Evaluation of serum cystatin C and chromogranin A as markers of nephropathy in patients with type 2 diabetes mellitus. Scand J Clin Lab Invest, 2000, 60:483-489.
  • 5Oddoze C, Morange S, Portugal H, et al. Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes. Am J Kidney Dis, 2001,38:310-316.
  • 6Dharnidharka VR,Kwon C,Stevens G. Serum Cystatin C is superior to serum creatinine as a marker of kidney function:a meta-analysis. Am J Kidney Dis, 2002,40:221-226.
  • 7Levey AS,Bosch JP,Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine:a new prediction equation. Ann Intern Med, 1999,130:461-470.
  • 8Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function-a review. Clin Chem Lab Med, 1999,37:389-395.
  • 9Dharnidharka VR,Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function : a meta-analysis.Am J Kidney Dis,2002,40:221-226.
  • 10National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.Am J Kidney Dis,2002,39(2 Suppl 1 ) :S1-266.

共引文献563

同被引文献60

  • 1涂盛,邵安文,叶真,姚定国.肝源性糖尿病发病机制研究进展[J].中华肝脏病杂志,2014,22(1). 被引量:23
  • 2翁建平.糖尿病肾病的诊断与治疗[J].临床内科杂志,2005,22(3):150-153. 被引量:79
  • 3张关亭,李志毅.血清胱抑素、视黄醇结合蛋白、尿微量白蛋白检测对原发性高血压肾病的早期诊断价值[J].慢性病学杂志,2010,12(12):1656-1656. 被引量:13
  • 4张建国,丁涵露,任姜汶.糖尿病肾病早期诊治新进展[J].华南国防医学杂志,2006,20(2):30-33. 被引量:17
  • 5Ekberg G, Grefberg N, Larsson O, et al. Relation between serum cholesterol and diabetic nephropathy[J]. Lancet, 1990, 336 (8720) : 954.
  • 6Shimizu A, Horikoshi S, Rinnno H, et al. Serum cystatin C may predict the early prognostic stages of patients with type 2 diabetic nephropathy[J]. J Clin Lab Anal, 2003, 17 (5) : 164-167.
  • 7Abrahamian H, Endler G, Exner M, et al. Association of low-grade inflammation with nephropathy in type 2 diabetic patients : role of elevated CRP-levels and 2 different gene- polymorphisms of proinflammatory cytokines[J]. Exp Clin Endocrinol Diabetes, 2007, 115 ( 1 ) : 38-41.
  • 8Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, et al. Features of endothelial dysfunction in early diabetic nephropathy[J]. Lancet, 1989, 1 (8636) : 461-463.
  • 9Pavkov ME, Knowler WC, Hanson RL, et al. Comparison of serum cystatin C, serum creatinine, measured GFR, and estimated GFR to assess the risk of kidney failurein American Indians with diabetic nephropathy[J]. Am J Kidney Dis, 2013, 62 (1) : 33-41.
  • 10Christensson AG, Grubb AO, Nilsson JA, et al. Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy[J]. J Intern Med, 2004, 256 (6) : 510-518.

引证文献10

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部